Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 9/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220458 | 0.92 | TBXA2R (0.57) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7468936 | 0.90 | TBXA2R (0.72) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9255961 | 0.88 | TBXA2R (0.61) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7218356 | 0.88 | TBXA2R (0.60) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7226903 | 0.87 | TBXAS1 (0.61) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7219571 | 0.86 | TBXAS1 (0.60) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL8114551 | 0.86 | TBXAS1 (0.60) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL8107247 | 0.85 | TBXAS1 (0.58) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7220602 | 0.85 | TBXAS1 (0.68) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL7220448 | 0.84 | TBXAS1 (0.58) | TBXA2RTBXAS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6545037-B2 | Thromboxane A2 (TXA2) receptor and 5HT2 serotonergic receptor antagonists; 3-(6-(((4-chlorophenyl)sulphonyl)amino)-3-((2-(4-methyl-1 -piperazinyl)phenoxy)methyl)-5,6, 7,8-tetrahydro-1-naphthyl)propanoic acid for example | LES LABORATOIRES SERVIER (FR) | 2003-04-08 | — | — | US | disclosed |
| US-6469011-B2 | NITROGEN OXIDE YIELDING AND THROMBOXANE A2 (TXA2) AND SEROTONIN (5HT2) RECEPTOR ANTAGONIST; TREATMENT OF ATHEROTHROMBOTIC CARDIOVASCULAR DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-10-22 | — | — | US | disclosed |
| US-20020137742-A1 | Benzenesulfonamide compounds | LAVIELLE GILBERT (FR) | 2002-09-26 | — | — | US | disclosed |
| US-20010009915-A1 | New benzenesulfonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009915-A1 | New benzenesulfonamide compounds | CNR1, CNR2, HTR1A | TBXA2R 5/4885TBXAS1 31/4885HDAC8 2046/4885 |
| US-20020137742-A1 | Benzenesulfonamide compounds | CNR1, CNR2, HTR1A | TBXA2R 4/4885TBXAS1 50/4885HDAC8 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.